Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial - Cheson, BD; Bartlett, NL; LaPlant, B (Lancet Haematol, 2020)
et al.